Novo and Lilly trade claims over who leads the GLP-1 pill race
Lilly says Foundayo has 40% of US new oral GLP-1 starts, but Novo's CEO says fuller data including telehealth gives the Wegovy pill about 80%. Novo reports 8 million Wegovy pill prescriptions since its January launch.
Source: BioSpace (4 Nov 2026). Image: BioSpace.